Literature DB >> 1872922

Serum lipids and apolipoproteins in patients with essential hypertension.

M Catalano1, A Aronica, G Carzaniga, R Seregni, A Libretti.   

Abstract

Fifty hypertensive untreated outpatients (34 women, 16 men), with stage I and II essential hypertension, were studied in comparison to 50 age- and sex-matched controls with similar life-styles. Total cholesterol triglycerides, LDL-cholesterol, VLDL-cholesterol, and HDL-cholesterol were measured by enzymatic methods, and apolipoproteins AI, AII, B, CII, CIII and E by RID. The results showed significant differences between hypertensives and controls respectively in triglycerides (135.2 +/- 73.9 versus 90.2 +/- 33.8, P less than 0.01) and VLDL cholesterol (26.7 +/- 14.8 versus 17.7 +/- 6.6, P less than 0.01) while no significant differences were observed in total, LDL and HDL cholesterol. Significant differences between the two groups were also observed in apolipoproteins, particularly in apo AI (130.0 +/- 28.2 versus 144.9 +/- 27.9, P less than 0.05), apo AII (32.9 +/- 10.2 versus 39.6 +/- 11.4, P less than 0.01), apo CII (4.0 +/- 2.6 versus 5.4 +/- 2.9, P less than 0.05) and apo E (5.0 +/- 1.8 versus 4.3 +/- 1.8, P less than 0.05), while no significant differences were observed in apo B and CIII values. The results suggest that in untreated hypertensive patients alterations in the apolipoproteins profile are present which, in part, may be responsible for the elevated incidence of cardiovascular disease, independently from the blood pressure values.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1872922     DOI: 10.1016/0021-9150(91)90228-u

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  3 in total

1.  Experimental challenges regarding the in vitro investigation of the nanoparticle-biocorona in disease states.

Authors:  Sherleen Xue-Fu Adamson; Zhoumeng Lin; Ran Chen; Lisa Kobos; Jonathan Shannahan
Journal:  Toxicol In Vitro       Date:  2018-05-05       Impact factor: 3.500

2.  From the Cover: Disease-Induced Disparities in Formation of the Nanoparticle-Biocorona and the Toxicological Consequences.

Authors:  Jonathan H Shannahan; Kristofer S Fritz; Achyut J Raghavendra; Ramakrishna Podila; Indushekar Persaud; Jared M Brown
Journal:  Toxicol Sci       Date:  2016-06-02       Impact factor: 4.849

3.  Effectiveness of blood pressure-lowering drug treatment by levels of absolute risk: post hoc analysis of the Australian National Blood Pressure Study.

Authors:  Chau Le Bao Ho; Monique Breslin; Jenny Doust; Christopher M Reid; Mark R Nelson
Journal:  BMJ Open       Date:  2018-03-19       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.